Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 12/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988985 | 0.85 | P2RX7 (0.40) | P2RX7EPHX2 | |
| SCHEMBL5543837 | 0.83 | P2RX7 (0.43) | P2RX7EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL4515453 | 0.78 | S1PR1 (0.38) | P2RX7 | |
| SCHEMBL4523525 | 0.78 | P2RX7 (0.44) | P2RX7EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL4513747 | 0.78 | MMP13 (0.38) | P2RX7 | |
| SCHEMBL5541273 | 0.76 | HSD11B1 (0.49) | P2RX7EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL2993186 | 0.76 | P2RX7 (0.40) | P2RX7 | |
| SCHEMBL4510565 | 0.75 | S1PR1 (0.39) | — | |
| SCHEMBL2989024 | 0.75 | P2RX7 (0.41) | P2RX7 | |
| SCHEMBL4513610 | 0.74 | FFAR4 (0.37) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | P2RX7 3946/4885EPHX2 670/4885CYP2C9 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.